Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390884 · ClinicalTrials.gov registry record · Phase 4
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 173
- Enrollment target
NCT00390884 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 173 participants.
The verdict
NCT00390884, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 173 participants
- Enrollment target
Study Summary
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
Interventions
- BIOLOGICAL Influenza Virus Vaccine, Fluzone®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390884
The ClinicalTrials.gov registry entry for NCT00390884 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine, Fluzone® is the first listed.
NCT00390884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390884 about?
NCT00390884 is a clinical study titled "Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.". To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
What is the current status of trial NCT00390884?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 173 participants. The study started on 2006-10. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00390884?
The interventions under investigation include: Influenza Virus Vaccine, Fluzone® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00390884?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.